TABLE 4

HRs (95% CI) of 5-year mortality in people with type 2 diabetes of the Casale Monferrato Study

All-cause mortality
Cardiovascular mortality
Number of deathsHR (95% CI) for CRP >3.0 mg/lNumber of deathsHR (95% CI) for CRP >3.0 mg/l
Men2621.41 (1.02–1.96)1051.61 (0.94–2.74)
Women2341.66 (1.14–2.41)1181.51 (0.88–2.57)
Subjects without CVD at baseline
    All cohort3391.67 (1.24–2.24)1331.36 (0.83–2.24)
    Men1711.55 (1.03–2.32)571.11 (0.52–2.37)
    Women1681.71 (1.09–2.69)761.62 (0.82–3.22)
A1C (%)
    ≤6.72161.54 (1.08–2.19)891.20 (0.67–2.14)
    >6.72681.51 (1.07–2.11)1281.56 (0.94–2.57)
Diabetes duration (years)
    ≤8.72021.60 (1.11–2.32)761.29 (0.70–2.40)
    >8.72911.48 (1.06–2.06)1441.54 (0.94–2.51)
LDL cholesterol (mg/dl)
    ≤1262651.38 (1.00–1.90)951.41 (0.80–2.50)
    >1281991.72 (1.18–2.50)1101.49 (0.91–2.46)
HDL cholesterol (mg/dl)
    ≤512371.55 (1.09–2.21)1091.50 (0.88–2.54)
    >512421.52 (1.08–2.14)1061.45 (0.84–2.49)
Central obesity
    No2411.40 (0.98–1.99)1021.46 (0.83–2.58)
    Yes2551.71 (1.20–2.43)1211.48 (0.88–2.50)
  • HRs adjusted for age, sex, diabetes duration, LDL and HDL cholesterol, A1C, smoking status, CVD, AER, diabetes treatment, waist circumference, and statins, apart from the stratification variable.